Synairgen has entered a partnership to support the Universal trial being led by the Clinical Trials Unit of the University of Southampton in the UK to potentially develop antivirals for viral infections.
The observational study will assess the diverse nature of acute respiratory viral infections and recovery in hospitalised patients with respiratory symptoms.
It seeks to develop a potential longitudinal clinical database of respiratory viral infections in hospitalised people.
This could aid in developing antivirals for severe viral lung infections caused by seasonal viruses and emergent viral threats.
The trial plans to recruit 1,000 subjects at 10 sites in the UK. They will be assessed for a period of 12 months.
The first subject in the trial was enrolled on 1 September this year.
Samples will be collected from hospitalised patients infected with various respiratory viruses.
Analysing the occurrence of various respiratory viruses in trial subjects during the winter season, as well as the clinical and biological predictors of disease progression, recovery, and length of hospital stay, are the trial’s primary endpoints.
The study will also offer an enhanced understanding of acute respiratory viral infection’s natural history and recovery to boost clinical management for identifying intervention options in people at severe disease development risk.
Synairgen is offering its viral testing equipment and nursing staff at the Southampton clinical trial site for the trial, which will be funded by Janssen.
Since UNIVERSAL is an observational trial, no therapies will be assessed, the company noted.
Synairgen CEO Richard Marsden said: “Our collaboration on the UNIVERSAL trial will help provide a better understanding of what could predict clinical outcomes in patients hospitalised with respiratory symptoms due to infection with a range of respiratory viruses.
“The UNIVERSAL trial will help to further inform the development programme of SNG001, our investigational broad-spectrum antiviral.”
In March this year, the company temporarily stopped the ACTIV-2 Phase III trial of SNG001 for Covid-19.